Fig. 4: Single-agent dose–response for ALKi in diagnosis and relapse eIMS xenografts. | British Journal of Cancer

Fig. 4: Single-agent dose–response for ALKi in diagnosis and relapse eIMS xenografts.

From: CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma

Fig. 4

Tumour growth curves, PPTC objective response and Kaplan–Meier survival analysis of diagnosis and relapse eIMS xenografts treated with a–d crizotinib or e–h ceritinib. Vehicle-control groups are three to six mice and treatment groups are four to six mice. *: Comparison of treatment group to vehicle-control group. #: Comparison to lowest dose treatment group. γ: Comparison of highest dose treatment group to middle dose treatment group. *P < 0.05, **P < 0.01, (Mantel–Cox Test).

Back to article page